• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

放疗设施容量对接受保膀胱治疗的肌层浸润性膀胱癌患者的生存和指南一致性的影响。

The Impact of Radiotherapy Facility Volume on the Survival and Guideline Concordance of Patients With Muscle-invasive Bladder Cancer Receiving Bladder-preservation Therapy.

机构信息

Department of Radiation Oncology, The University of Kansas School of Medicine, Kansas City, KS.

出版信息

Am J Clin Oncol. 2019 Sep;42(9):705-710. doi: 10.1097/COC.0000000000000582.

DOI:10.1097/COC.0000000000000582
PMID:31368905
Abstract

OBJECTIVES

Higher facility surgical volume predicts for improved outcomes in patients with muscle-invasive bladder cancer (MIBC) who undergo radical cystectomy. We investigated the association between facility radiotherapy (RT) case volume and overall survival (OS) for patients with MIBC who received bladder-preserving RT, and the relationship with adherence to National Comprehensive Cancer Network (NCCN) guidelines for bladder preservation.

METHODS

The National Cancer Database was used to identify patients diagnosed with nonmetastatic MIBC from 2004 to 2015 and received RT at the reporting center. Facility case volume was defined as the total MIBC patients treated with RT during the period. Facilities were stratified into high-volume facility (HVF) or low-volume facility at the 80th percentile of RT case volume. OS was assessed using Kaplan-Meier analysis. Rates of compliance with NCCN guidelines regarding the use of transurethral resection of the bladder tumor before RT, planned use of concurrent chemotherapy, and total RT dose were compared. Cox proportional hazard model was used to evaluate predictors of OS.

RESULTS

There were 7562 patients included. No differences in age, Charlson-Deyo score, T stage, or node-positive rates were observed between groups. HVFs exhibited greater compliance with NCCN guidelines for bladder preservation (P<0.0001). Treatment at an HVF was associated with the improved OS for all patients (P=0.001) and for the subset of patients receiving NCCN-recommended RT doses (P=0.0081). Volume was an independent predictor of OS (P=0.002).

CONCLUSIONS

Treatment at an HVF is associated with improved OS and greater guideline-concordant management among patients with MIBC.

摘要

目的

更高的手术设施量可预测接受根治性膀胱切除术的肌层浸润性膀胱癌(MIBC)患者的预后改善。我们调查了设施放疗(RT)病例量与接受膀胱保留 RT 的 MIBC 患者的总生存(OS)之间的关联,以及与遵守国家综合癌症网络(NCCN)膀胱保留指南之间的关系。

方法

使用国家癌症数据库,确定了 2004 年至 2015 年间诊断为非转移性 MIBC 并在报告中心接受 RT 的患者。设施病例量定义为同期接受 RT 治疗的 MIBC 总患者数。设施按照 RT 病例量的第 80 百分位数分为高容量设施(HVF)或低容量设施。使用 Kaplan-Meier 分析评估 OS。比较 RT 前膀胱肿瘤经尿道切除术、计划使用同期化疗和总 RT 剂量使用 NCCN 指南的合规率。Cox 比例风险模型用于评估 OS 的预测因素。

结果

共纳入 7562 例患者。两组患者在年龄、Charlson-Deyo 评分、T 分期或淋巴结阳性率方面无差异。HVF 表现出更高的遵守 NCCN 膀胱保留指南(P<0.0001)。在 HVF 治疗与所有患者的 OS 改善相关(P=0.001),也与接受 NCCN 推荐 RT 剂量的患者亚组相关(P=0.0081)。体积是 OS 的独立预测因素(P=0.002)。

结论

在 MIBC 患者中,在 HVF 治疗与 OS 改善和更大程度的指南一致管理相关。

相似文献

1
The Impact of Radiotherapy Facility Volume on the Survival and Guideline Concordance of Patients With Muscle-invasive Bladder Cancer Receiving Bladder-preservation Therapy.放疗设施容量对接受保膀胱治疗的肌层浸润性膀胱癌患者的生存和指南一致性的影响。
Am J Clin Oncol. 2019 Sep;42(9):705-710. doi: 10.1097/COC.0000000000000582.
2
Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer.比较肌层浸润性膀胱癌行放化疗与根治性膀胱切除术的生存预后的倾向评分匹配分析。
BJU Int. 2018 May;121(5):745-751. doi: 10.1111/bju.14109. Epub 2018 Jan 22.
3
Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.新辅助化疗在非转移性肌层浸润性膀胱癌患者膀胱保留放化疗前的应用。
Clin Genitourin Cancer. 2019 Feb;17(1):38-45. doi: 10.1016/j.clgc.2018.09.021. Epub 2018 Oct 4.
4
Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.接受根治性膀胱切除术或膀胱保留治疗的肌层浸润性膀胱癌患者的当代使用趋势和生存结果。
Cancer. 2017 Nov 15;123(22):4337-4345. doi: 10.1002/cncr.30900. Epub 2017 Jul 25.
5
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.保留膀胱的三联疗法治疗肌层浸润性膀胱癌患者的长期疗效:马萨诸塞州综合医院经验的更新分析。
Eur Urol. 2017 Jun;71(6):952-960. doi: 10.1016/j.eururo.2016.12.020. Epub 2017 Jan 9.
6
The Impact of Academic Facility Type and Case Volume on Survival in Patients Undergoing Curative Radiation Therapy for Muscle-Invasive Bladder Cancer.学术设施类型和病例量对接受根治性放疗的肌层浸润性膀胱癌患者生存的影响。
Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):851-857. doi: 10.1016/j.ijrobp.2017.11.040. Epub 2017 Dec 5.
7
Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base.美国肌肉浸润性膀胱癌潜在治愈疗法的使用:来自国家癌症数据库的结果。
Eur Urol. 2013 May;63(5):823-9. doi: 10.1016/j.eururo.2012.11.015. Epub 2012 Nov 19.
8
EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer.欧洲癌症研究与治疗组织进展评分可识别接受根治性膀胱切除术治疗继发性肌层浸润性膀胱癌后癌症特异性死亡风险高的患者。
Clin Genitourin Cancer. 2014 Aug;12(4):278-86. doi: 10.1016/j.clgc.2013.11.014. Epub 2013 Nov 13.
9
Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.同期化疗与接受放疗的老年膀胱癌患者的生存改善相关。
Cancer. 2017 Sep 15;123(18):3524-3531. doi: 10.1002/cncr.30719. Epub 2017 Jun 5.
10
Comparing long-term outcomes of primary and progressive carcinoma invading bladder muscle after radical cystectomy.根治性膀胱切除术后原发性和进展性癌侵犯膀胱肌肉的长期预后比较。
BJU Int. 2016 Apr;117(4):604-10. doi: 10.1111/bju.13146. Epub 2015 Jun 3.

引用本文的文献

1
Survival analysis of the non-metastatic cohort of the Italian Association for Medical Oncology (AIOM) Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy (GARIBALDI).意大利医学肿瘤学会(AIOM)在现实世界中应用指南的非转移性队列生存分析:意大利辅助和一线胰腺导管腺癌治疗的多机构调查(GARIBALDI)
ESMO Open. 2025 Jan;10(1):104001. doi: 10.1016/j.esmoop.2024.104001. Epub 2025 Jan 3.
2
Radiation Facility Volume and Survival for Men With Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy.接受放疗和雄激素剥夺治疗的极高危前列腺癌男性的放射治疗设施量与生存。
JAMA Netw Open. 2023 Aug 1;6(8):e2327637. doi: 10.1001/jamanetworkopen.2023.27637.
3
Systematic Review and Meta-analysis of the Association Between Radiation Therapy Treatment Volume and Patient Outcomes.系统评价和荟萃分析放射治疗治疗体积与患者结局的关系。
Int J Radiat Oncol Biol Phys. 2023 Dec 1;117(5):1063-1086. doi: 10.1016/j.ijrobp.2023.02.048. Epub 2023 May 25.
4
Socioeconomic Disparities in Surgical Care for Congenital Hand Differences.先天性手部差异手术治疗中的社会经济差异。
Hand (N Y). 2024 Jan;19(1):104-112. doi: 10.1177/15589447221092059. Epub 2022 May 24.
5
Management of Localized Muscle-Invasive Bladder Cancer from a Multidisciplinary Perspective: Current Position of the Spanish Oncology Genitourinary (SOGUG) Working Group.从多学科角度看局限性肌肉浸润性膀胱癌的治疗:西班牙肿瘤泌尿学组(SOGUG)工作组的当前立场。
Curr Oncol. 2021 Dec 3;28(6):5084-5100. doi: 10.3390/curroncol28060428.
6
A Novel DNA Methylation Signature as an Independent Prognostic Factor in Muscle-Invasive Bladder Cancer.一种新型DNA甲基化特征作为肌层浸润性膀胱癌的独立预后因素
Front Oncol. 2021 Feb 15;11:614927. doi: 10.3389/fonc.2021.614927. eCollection 2021.
7
Analysis of Radiation Facility Volume and Survival in Men With Lymph Node-Positive Prostate Cancer Treated With Radiation and Androgen Deprivation Therapy.分析接受放疗和雄激素剥夺治疗的淋巴结阳性前列腺癌男性的辐射设施容积和生存情况。
JAMA Netw Open. 2020 Dec 1;3(12):e2025143. doi: 10.1001/jamanetworkopen.2020.25143.
8
Bladder preservation in muscle-invasive bladder cancer: a comprehensive review.肌层浸润性膀胱癌的膀胱保留治疗:全面综述。
Int Braz J Urol. 2020 Mar-Apr;46(2):169-184. doi: 10.1590/S1677-5538.IBJU.2020.99.01.